ZUH:CA:TSX-BMO Equal Weight US Health Care (CAD Hedged) (CAD)

ETF | Sector Equity |

Last Closing

CAD 71.25

Change

+0.31 (+0.44)%

Market Cap

CAD 0.27B

Volume

500.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Sector Equity

Symbol Name Price(Change) Market Cap
TEC:CA TD Global Technology Leaders I..

+0.51 (+1.28%)

CAD 2.91B
ZWU:CA BMO Covered Call Utilities ETF

-0.02 (-0.18%)

CAD 1.94B
XHC:CA iShares Global Healthcare (CAD..

+0.13 (+0.18%)

CAD 0.65B
XIT:CA iShares S&P/TSX Capped Informa..

+1.24 (+2.16%)

CAD 0.65B
TXF:CA First Asset Tech Giants Covere..

+0.26 (+1.21%)

CAD 0.65B
HTA:CA Harvest Tech Achievers Growth ..

+0.24 (+1.26%)

CAD 0.63B
ZUT:CA BMO Equal Weight Utilities Ind..

+0.06 (+0.27%)

CAD 0.45B
CWW:CA iShares Global Water Common Cl..

N/A

CAD 0.34B
XUT:CA iShares S&P/TSX Capped Utiliti..

+0.04 (+0.14%)

CAD 0.32B
COW:CA iShares Global Agriculture Com..

+0.64 (+1.02%)

CAD 0.28B

ETFs Containing ZUH:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Sector Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.49% 23% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.49% 23% F 25% F
Trailing 12 Months  
Capital Gain 10.21% 23% F 34% F
Dividend Return 0.78% 32% F 18% F
Total Return 10.99% 17% F 32% F
Trailing 5 Years  
Capital Gain 36.70% 37% F 61% D-
Dividend Return 2.25% 22% F 10% F
Total Return 38.96% 29% F 55% F
Average Annual (5 Year Horizon)  
Capital Gain 4.87% N/A N/A 55% F
Dividend Return 5.25% N/A N/A 52% F
Total Return 0.38% N/A N/A 26% F
Risk Return Profile  
Volatility (Standard Deviation) 16.63% N/A N/A 71% C-
Risk Adjusted Return 31.56% N/A N/A 51% F
Market Capitalization 0.27B 71% C- 50% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.